
Regeneron Faces Securities Lawsuit Over Clinical Trial Disclosures
Investors who purchased Regeneron Pharmaceuticals stock between August 1, 2025, and May 15, 2026, face a September 14, 2026, deadline to seek lead plaintiff status in a class action lawsuit. The litigation centers on claims that the company misled shareholders regarding the risks of its Phase III Fianlimab-Libtayo clinical trial.


























